Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051675 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas
A Phase 1 study, sponsored by Xoma (US).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00051675 is a Phase 1 study that has completed, run by Xoma (US). The registered enrollment target is 30 participants.
The verdict
NCT00051675, a Phase 1 study, has completed, sponsored by Xoma (US).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, immunogenicity, and tolerability of a monoclonal antibody administered subcutaneously in the treatment of advanced cancers of the ovary, breast, lung, prostate, colon or rectum that are either refractory to standard therapies or for which therapies that may potentially be of major benefit do not exist.
Interventions
- DRUG ING-1(heMAb)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-07 |
| Est. Completion | 2003-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00051675
The ClinicalTrials.gov registry entry for NCT00051675 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xoma (US), which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ING-1(heMAb) is the first listed.
NCT00051675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00051675 about?
NCT00051675 is a clinical study titled "Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas". The purpose of this study is to evaluate the safety, immunogenicity, and tolerability of a monoclonal antibody administered subcutaneously in the treatment of advanced cancers of the ovary, breast, lung, prostate, colon or rectum that are either refractory to standard therapies or for which therapie...
What is the current status of trial NCT00051675?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2002-07. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00051675?
The interventions under investigation include: ING-1(heMAb) (DRUG).
Who is sponsoring clinical trial NCT00051675?
This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.